LAS VEGAS, Dec. 13, 2017 /PR Newswire/ -- GB Sciences, Inc. (OTCQB: GBLX) is proud to announce its development of a cannabis strain that has an extremely high THC concentration, and also has a specifically-defined terpene profile, meaning that this potent strain may have significant medical benefits.
The team was gratified to receive hard test results that verified their goal. The plant produced a THC-a content of 35.119%, as well as β-myrcene levels of 2.18% and β-caryophyllene levels of 1.01%, as tested by independent lab Digipath Labs, Inc. in Las Vegas.
"Because of our research background, we're not willing to talk about things while we have only anecdotal evidence. But now, we have solid data that shows that the innovations that we have been working on for years are starting to bear fruit," said Chief Science Office, Dr. Andrea Small-Howard.
This strain is the result of an ongoing research project and is one of many tangible results of the coordination of the three operating units--- Life Sciences, Tissue Propagation, and Cultivation Labs. GB Sciences is a fully integrated cannabis company with three complementary operating units. The internal pipeline is now fully solidified; the Life Sciences division researches and develops the profile for a strain that is thought to be medicinally important; the Tissue Propagation team acquires the specified genetics and begins the propagation process to provide clean, healthy, starter plants so that verifiable and consistent results can be gained; the new plants then move into the Cultivation Labs precision controlled growing environment and are matured under stringently monitored growing conditions.
Mr. Kevin Kuethe, COO remarked, "GB Sciences is perfecting cannabis genetics. Everything we do is based in science and that involves testing and verifying every aspect of the process. Our precision controlled growing environment is now fully dialed in, and the high THC percentages and terpene levels in our premium genetics benefit both the medical formulation needs and the Adult Use market."
Dr. Ulrich Reimann-Philipp, Chief Botanist stated, "We use our biotech tissue propagation to maximize the genetic potential of each strain. And our precision controlled growing environments are adjusted constantly to ensure that the full potential is delivered. We are now sure that we have found the conditions that allow us to get the most that each particular strain has to offer."
Dr. Andrea Small-Howard, Chief Science Officer, said "The development of this strain is itself a remarkable achievement, but more importantly it shows that the GB Sciences divisional approach works, and works very efficiently. The excitement of coordinating a relatively large-scale effort in our relatively small company cannot be overstated; it proves that even while operating within the restrictive confines of Federal law, we can do something meaningful that will ultimately result in great advances in the treatment of many diseases for patients around the world. Research is in our corporate DNA."
About GB Sciences, Inc.
GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
View original content with multimedia:http://www.prnewswire.com/news-releases/gb-sciences-develops-extremely-high-thc-content-cannabis-strain-with-maximized-terpene-levels-to-increase-medical-benefits-300570463.html
SOURCE GB Sciences, Inc.